Scrip is part of the Informa Intelligence Division of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By


Northera NDA resubmission expected late 2Q; Chelsea rockets

This article was originally published in Scrip

Executive Summary

Shares of Chelsea Therapeutics rocketed as high as 172% on 20 February on word the US FDA would be willing to accept the firm's recently completed Phase III 306B study as the basis for a resubmission of the new drug application (NDA) for Northera (droxidopa) – a drug that has kept investors on a rollercoaster ride for much of the past year – with the potential the company could have a decision in hand by the end of the year.



Related Companies




Ask The Analyst

Please Note: Click here for more information on the Ask the Analyst service.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts